Utama › Kanser Endometrium › Florida › Tampa
Kajian klinikal Kanser Endometrium di Tampa, FL
15 kajian untuk Kanser Endometrium sedang mencari peserta di lokasi dalam dan sekitar Tampa (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Study of AVZO-021 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Mengambil pesertaFasa 1
- Moffitt, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Mengambil pesertaFasa 1/2
- Moffitt Cancer Center and Research Institute, Tampa
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Mengambil pesertaFasa 3
- Women's Care - Armenia Ave, Tampa
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Mengambil pesertaFasa 3
- Research Site, Tampa
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., Tampa
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Moffitt Cancer Center, Tampa
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Mengambil pesertaFasa 3
- Research Site, Tampa
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
- Investigative Site #128, Tampa
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Moffitt Cancer Center, Tampa
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Mengambil pesertaFasa 1
- Moffitt Cancer Center, Tampa
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Mengambil pesertaFasa 1/2
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Mengambil pesertaFasa 1/2
- Moffitt Cancer Center and Research Institute, Tampa
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Mengambil pesertaFasa 2
- H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Tampa
Kajian Kanser Endometrium di bandar lain
- Houston, TX68 kajian
- New York City, NY52 kajian
- Boston, MA50 kajian
- Arlington, VA39 kajian
- Nashville, TN38 kajian
- Los Angeles, CA34 kajian
- St. Louis, MO29 kajian
- Philadelphia, PA28 kajian
- San Antonio, TX27 kajian
- Columbus, OH25 kajian
- Oklahoma City, OK25 kajian
- Chicago, IL25 kajian
Kajian lain di Tampa
- Kanser Paru-paru Bukan Sel Kecil51 kajian
- Kanser Payudara43 kajian
- Kanser (semua jenis)39 kajian
- Kanser Kolorektal34 kajian
- Leukemia Mieloid Akut29 kajian
- Kanser Metastatik29 kajian
- Kanser Paru-paru29 kajian
- Kanser Pankreas26 kajian
- Kanser Ovari21 kajian
- Melanoma19 kajian
- Sindrom Mielodisplastik19 kajian
- Kanser Prostat18 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.